Intellia develops CRISPR gene editing treatments for severe diseases, with lead candidates in late stage clinical trials. NTLA reports earnings on Thu, Nov 5, 2026. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 1 hold, 1 sell). In the past 30 days there were 3 dark pool prints.
Prices, price targets and earnings estimates for NTLA are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTLA is in one of them and how their past NTLA trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Intellia Therapeutics
Intellia is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments using CRISPR gene editing. Its lead candidates are designed to address the underlying cause of rare, severe diseases, including hereditary angioedema and ATTR amyloidosis, and are given as a single intravenous infusion. The company's lead candidates are in late stage clinical trials, and it is preparing for possible commercial launches aimed at patients with these conditions. It also works with partners, such as Regeneron, on additional programs.
